| 2.12 -0.125 (-5.57%) | 07-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.84 | 1-year : | 4.48 |
| Resists | First : | 3.28 | Second : | 3.84 |
| Pivot price | 1.87  |
|||
| Supports | First : | 1.36 | Second : | 0.18 |
| MAs | MA(5) : | 2.31  |
MA(20) : | 1.46 |
| MA(100) : | 0.76 |
MA(250) : | 0.89 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 65.5 |
D(3) : | 68.8 |
| RSI | RSI(14): 65.2 |
|||
| 52-week | High : | 3.28 | Low : | 0.13 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VOR ] has closed below upper band by 40.4%. Bollinger Bands are 283.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.37 - 2.39 | 2.39 - 2.4 |
| Low: | 1.89 - 1.91 | 1.91 - 1.92 |
| Close: | 2.09 - 2.12 | 2.12 - 2.14 |
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Thu, 17 Jul 2025
Vor Bio Strengthens Leadership: Telitacicept Expert With Multiple Drug Approvals Joins as Development Chief - Stock Titan
Wed, 16 Jul 2025
Vor Biopharma Faces Crucial Market Shifts Amid Latest Developments - StocksToTrade
Wed, 16 Jul 2025
Vor Biopharma Stock Faces Volatile Week Amid Mixed Financial Reports - timothysykes.com
Mon, 14 Jul 2025
Vor Biopharma Stock’s Rollercoaster: Time to Buy? - StocksToTrade
Tue, 08 Jul 2025
Vor Biopharma Shares Soar 23.22% on Analyst Upgrades - AInvest
Tue, 08 Jul 2025
Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 125 (M) |
| Shares Float | 39 (M) |
| Held by Insiders | 31.8 (%) |
| Held by Institutions | 48.4 (%) |
| Shares Short | 3,220 (K) |
| Shares Short P.Month | 2,760 (K) |
| EPS | -1.51 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.52 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -55.3 % |
| Return on Equity (ttm) | -125.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -100 (M) |
| Levered Free Cash Flow | -62 (M) |
| PE Ratio | -1.41 |
| PEG Ratio | 0 |
| Price to Book value | 4 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.65 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|